Begin main content

Vectibix for Left Sided Metastatic Colorectal Cancer — Details

Project Number pCODR 10118
Brand Name Vectibix
Generic Name Panitumumab
Tumour Type Gastrointestinal
Indication Left Sided Metastatic Colorectal Cancer
Funding Request In combination with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS
Review Status Pending
Pre Noc Submission No
NOC Date
Manufacturer Amgen Canada Inc.
Submitter Amgen Canada Inc.
Submission Date September 8, 2017
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ September 22, 2017
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.